Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement (NCT06146504) | Clinical Trial Compass
CompletedNot Applicable
Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement
United States60 participantsStarted 2023-11-30
Plain-language summary
This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12. Candida microbiome testing will be conducted via stool sample at Baseline and Week 12.
The participants will all be blinded to the name of the test brand.
Who can participate
Age range18 Years – 50 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. May also experience issues with fatigue, lethargy, and gut or digestive issues.
✓. Willing to provide two stool samples during the study.
✓. Willing to adhere to the study protocol.
✓. Willing to avoid introducing any products or any new forms of regular medication or supplements that target candida overgrowth, gut health, or vaginal health for the duration of the study.
Exclusion criteria
✕. Anyone with severe chronic conditions including oncological conditions, psychiatric disease, diabetes, or other.
✕. Anyone with known severe allergic reactions or is allergic to the test product or placebo ingredients.
✕. Currently taking any antibiotics or will be during the trial period.
✕. Anymore diagnosed with a sexually transmitted disease within the last three months e.g. Chlamydia, trichomoniasis, gonorrhea, genital herpes
✕. Women who are pregnant, breastfeeding, or attempting to become pregnant.
✕. Having any planned invasive medical procedures during the study period.
What they're measuring
1
Changes in growth of candida in the gut. [Timeframe: Baseline to Week 12]